ThromboGenics Provides Update on Strategic Review Process

FlandersBio's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

24/06/2014

In response to market rumors, ThromboGenics NV (Euronext Brussels: THR) today issues an update on the Strategic Review process that was initiated in February 2014.

Following an assessment of various strategic options including a sale of the entire company, the Board of Directors of ThromboGenics has decided to continue as a stand-alone company, and to pursue discussions for a potential partnership for the commercialization of JETREA in the US. The Company will provide a further update at the time of its 2014 half year reporting on August 28.

Separately, Chris Buyse, Chief Financial Officer and Board Member of ThromboGenics, will resign effective June 30, 2014. Chris was appointed CFO of ThromboGenics following its 2006 IPO and has played an important role in building ThromboGenics.

As of July 1, Luc Philips, former CFO of KBC group and Board Member of ThromboGenics since its IPO, will take on the role of interim-CFO until the Company completes an international search for a new permanent CFO.

News Source : ThromboGenics Provides Update on Strategic Review Process
Copy this html code to your website/blog to embed this press release.